Oxford and Serum Institute begin initial human trials for Ebola vaccine
The Serum Institute of India and the University of Oxford have kicked off the first-ever human clinical trials for the ChAdOx1 BDBV vaccine. This shot targets the Bundibugyo strain of Ebola, a virus that lacks any authorized vaccine. This Phase I trial involves 50 healthy participants to evaluate the vaccine's safety and how well it triggers an immune response, representing a significant step forward in preparing for future global outbreaks.
by shortkt.com✓